Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study

V. Liska, V. Treska, T. Skalicky, J. Fichtl, J. Bruha, O. Vycital, O. Topolcan, R. Palek, J. Rosendorf, J. Polivka, L. Holubec,

. 2017 ; 37 (4) : 2003-2009.

Jazyk angličtina Země Řecko

Typ dokumentu hodnotící studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023162

BACKGROUND/AIM: The behavior of tumor markers in biliary tract malignancies is not well-known and has been scarcely studied. Such markers could play important roles in diagnostic and prognostic schemes as well as in decision-making about the best treatment strategies. This study analyzed the preoperative serum levels of conventional tumor markers (AFP, CEA, CA 19-9, CA 72-4), proliferative marker thymidine kinase (TK) and cytokeratins (TPA, TPS and CYFRA 21.1) in patients with gallbladder carcinoma, bile duct carcinoma (Klatskin) and cholangiocellular carcinoma, in relation to the patient prognosis. The study aimed in finding the role of tumor markers in not properly investigated diseases, where their importance is often marginalized. MATERIALS AND METHODS: The study included 43 patients, who underwent either radical surgical procedure (n=21) or explorative laparotomy without any surgical treatment (n=22) for gallbladder carcinoma, bile duct carcinoma (Klatskin tumor) and cholangiocellular carcinoma (24, 8 and 11 patients, respectively) between 2003 and 2010 at our Department. The association of serum tumor markers and patients' prognosis were assessed for the entire cohort and for each cancer type and also with regard to treatment (radical surgery versus explorative laparotomy). Overall survival (OS) and disease-free interval (DFI) were estimated by the Kaplan-Meier method and statistically evaluated using the LogRank test. DFI was computed only in the subgroup of patients treated by radical surgery. RESULTS: The statistical analysis of tumor markers revealed TK as a poor prognostic factor for shorter DFI (HR=3.5, 95%CI=0.6-21.3, p<0.05) and also OS (HR=4.6, 95%CI=1.0-4.7, p<0.05) in patients with gallbladder carcinoma treated with radical surgery. TPS was demonstrated as a poor prognostic factor for OS in patients with gallbladder carcinoma (HR=12.7, 95%CI=1.4-117.7, p<0.05). CEA was proven to be a factor of poor prognosis with shorter OS in patients after explorative laparotomy for all cumulated studied diagnoses (HR=9.8, 95%CI=1.05-92.7, p<0.05). CONCLUSION: The results of this study suggested the importance of tumor markers for assessment of prognosis (OS or DFI) in patients with gallbladder carcinoma, bile duct carcinoma, and cholangiocellular carcinoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023162
003      
CZ-PrNML
005      
20180605083744.0
007      
ta
008      
170720s2017 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.11544 $2 doi
035    __
$a (PubMed)28373474
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Liska, Vaclav $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic vena.liska@gmail.com. Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
245    10
$a Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study / $c V. Liska, V. Treska, T. Skalicky, J. Fichtl, J. Bruha, O. Vycital, O. Topolcan, R. Palek, J. Rosendorf, J. Polivka, L. Holubec,
520    9_
$a BACKGROUND/AIM: The behavior of tumor markers in biliary tract malignancies is not well-known and has been scarcely studied. Such markers could play important roles in diagnostic and prognostic schemes as well as in decision-making about the best treatment strategies. This study analyzed the preoperative serum levels of conventional tumor markers (AFP, CEA, CA 19-9, CA 72-4), proliferative marker thymidine kinase (TK) and cytokeratins (TPA, TPS and CYFRA 21.1) in patients with gallbladder carcinoma, bile duct carcinoma (Klatskin) and cholangiocellular carcinoma, in relation to the patient prognosis. The study aimed in finding the role of tumor markers in not properly investigated diseases, where their importance is often marginalized. MATERIALS AND METHODS: The study included 43 patients, who underwent either radical surgical procedure (n=21) or explorative laparotomy without any surgical treatment (n=22) for gallbladder carcinoma, bile duct carcinoma (Klatskin tumor) and cholangiocellular carcinoma (24, 8 and 11 patients, respectively) between 2003 and 2010 at our Department. The association of serum tumor markers and patients' prognosis were assessed for the entire cohort and for each cancer type and also with regard to treatment (radical surgery versus explorative laparotomy). Overall survival (OS) and disease-free interval (DFI) were estimated by the Kaplan-Meier method and statistically evaluated using the LogRank test. DFI was computed only in the subgroup of patients treated by radical surgery. RESULTS: The statistical analysis of tumor markers revealed TK as a poor prognostic factor for shorter DFI (HR=3.5, 95%CI=0.6-21.3, p<0.05) and also OS (HR=4.6, 95%CI=1.0-4.7, p<0.05) in patients with gallbladder carcinoma treated with radical surgery. TPS was demonstrated as a poor prognostic factor for OS in patients with gallbladder carcinoma (HR=12.7, 95%CI=1.4-117.7, p<0.05). CEA was proven to be a factor of poor prognosis with shorter OS in patients after explorative laparotomy for all cumulated studied diagnoses (HR=9.8, 95%CI=1.05-92.7, p<0.05). CONCLUSION: The results of this study suggested the importance of tumor markers for assessment of prognosis (OS or DFI) in patients with gallbladder carcinoma, bile duct carcinoma, and cholangiocellular carcinoma.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x krev $7 D000951
650    _2
$a nádory žlučových cest $x krev $x patologie $7 D001650
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a antigen CA-19-9 $x krev $7 D018395
650    _2
$a cholangiokarcinom $x krev $x patologie $7 D018281
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nádory žlučníku $x krev $x patologie $7 D005706
650    _2
$a lidé $7 D006801
650    _2
$a imunoanalýza $7 D007118
650    _2
$a keratin-19 $x krev $7 D053539
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Treska, Vladislav $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Skalicky, Tomas $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Fichtl, Jakub $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Bruha, Jan $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Vycital, Ondrej $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Topolcan, Ondrej $u Central Immunoanalytical Laboratory, Faculty Hospital Plzen, Plzen, Czech Republic.
700    1_
$a Palek, Richard $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Rosendorf, Jáchym $u Department of Surgery, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. $7 xx0224963
700    1_
$a Polivka, Jiri $u Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. Department of Histology and Embryology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
700    1_
$a Holubec, Luboš, $d 1972- $7 xx0068645 $u Biomedical Center, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 37, č. 4 (2017), s. 2003-2009
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28373474 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20180605083947 $b ABA008
999    __
$a ok $b bmc $g 1238843 $s 984075
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 4 $d 2003-2009 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace